XSHE
300246
Market cap603mUSD
Oct 09, Last price
15.12CNY
1D
-0.98%
1Q
0.33%
Jan 2017
-31.98%
IPO
105.99%
Name
Guangdong Biolight Meditech Co Ltd
Chart & performance
P/E
—
P/S
3.65
EPS
—
Div yield, %
0.33%
Shrs. gr., 5y
3.84%
Rev. gr., 5y
0.08%
Revenues
1.10b
+3.29%
Net income
-69m
L-2.82%
CFO
90m
P
Dividend
Nov 26, 20250.05 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Guangdong Biolight Meditech Co., Ltd., founded in 1993 and headquartered in Zhuhai, China, operates as a global enterprise. The company is dedicated to the full spectrum of medical technology, encompassing the research, development, commercialization, sales, and after-sales service of various medical devices, consumables, and integrated healthcare solutions. Its extensive product portfolio includes patient and fetal monitors, ECG machines, hemodialysis equipment, homecare medical products, and specialized items such as medical pumps and veterinary monitors, along with related accessories. Biolight Meditech maintains a broad international footprint, delivering its offerings to markets across Asia, Africa, Europe, North America, and Latin America.
Key people
Wei Xu
Chief Financial Officer, Director · since 2025
Yongxing Yang
Vice President, Secretary of the Board · since 2022
Xiaoming Li
Director · since 2022
Jinyuan Yan
Chairman of the Board, President · since 2022
Jian Chen
Independent Director · since 2025
Jundong Xue
Independent Director · since 2022
Zhenxin Yang
Independent Director · since 2022
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||